G protein‐coupled receptor hetero‐dimerization: contribution to pharmacology and function

The concept that G protein‐coupled receptors (GPCRs) can form hetero‐dimers or hetero‐oligomers continues to gain experimental support. However, with the exception of the GABAB receptor and the sweet and umami taste receptors few reported examples meet all of the criteria suggested in a recent International Union of Basic and Clinical Pharmacology sponsored review ( Pin et al., 2007 ) that should be required to define distinct and physiologically relevant receptor species. Despite this, there are many examples in which pairs of co‐expressed GPCRs reciprocally modulate their function, trafficking and/or ligand pharmacology. Such data are at least consistent with physical interactions between the receptor pairs. In recent times, it has been suggested that specific GPCR hetero‐dimer or hetero‐oligomer pairs may represent key molecular targets of certain clinically effective, small molecule drugs and there is growing interest in efforts to identify ligands that may modulate hetero‐dimer function selectively. The current review summarizes key recent developments in these topics.

[1]  Stefan Offermanns,et al.  International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B) , 2011, Pharmacological Reviews.

[2]  G. Milligan,et al.  Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective α1b-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers , 2008, The Biochemical journal.

[3]  L. Miller,et al.  Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. , 2008, Biochimica et biophysica acta.

[4]  G. Milligan,et al.  Morphine Desensitization, Internalization, and Down-Regulation of the μ Opioid Receptor Is Facilitated by Serotonin 5-Hydroxytryptamine2A Receptor Coactivation , 2008, Molecular Pharmacology.

[5]  D. Nicholls,et al.  Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.

[6]  I. D. de Esch,et al.  Phenylalanine 169 in the Second Extracellular Loop of the Human Histamine H4 Receptor Is Responsible for the Difference in Agonist Binding between Human and Mouse H4 Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. Mamillapalli,et al.  Switching of G-protein Usage by the Calcium-sensing Receptor Reverses Its Effect on Parathyroid Hormone-related Protein Secretion in Normal Versus Malignant Breast Cells* , 2008, Journal of Biological Chemistry.

[8]  F. Ciruela,et al.  Detection of higher‐order G protein‐coupled receptor oligomers by a combined BRET–BiFC technique , 2008, FEBS letters.

[9]  Marta Filizola,et al.  Dopamine D2 receptors form higher order oligomers at physiological expression levels , 2008, The EMBO journal.

[10]  J. Mallol,et al.  Novel pharmacological targets based on receptor heteromers , 2008, Brain Research Reviews.

[11]  P. Spano,et al.  Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization , 2008, Molecular Pharmacology.

[12]  N. Tinel,et al.  Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.

[13]  K. Eidne,et al.  G protein-coupled receptor dimers: functional consequences, disease states and drug targets. , 2008, Pharmacology & therapeutics.

[14]  Vsevolod V Gurevich,et al.  How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.

[15]  S. Schiffmann,et al.  An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. , 2008, Current pharmaceutical design.

[16]  M. Bouvier,et al.  Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased Mitogen-Activated Protein Kinase Signaling through the β1-Adrenergic Receptor , 2008, Molecular Pharmacology.

[17]  Nagarajan Vaidehi,et al.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.

[18]  Wayne A Hendrickson,et al.  Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor , 2008, EMBO reports.

[19]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[20]  G. Milligan A day in the life of a G protein‐coupled receptor: the contribution to function of G protein‐coupled receptor dimerization , 2008, British journal of pharmacology.

[21]  F. Ciruela,et al.  G‐protein‐coupled receptor heteromers: function and ligand pharmacology , 2008, British journal of pharmacology.

[22]  L. Hunyady,et al.  Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. , 2008, The Journal of endocrinology.

[23]  G. Milligan,et al.  CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2–DOP receptor heterodimer , 2008, The Biochemical journal.

[24]  Krzysztof Palczewski,et al.  Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid Bilayer* , 2008, Journal of Biological Chemistry.

[25]  K. Lorenz,et al.  Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. , 2008, Nature chemical biology.

[26]  Thomas Bäck,et al.  GPCR NaVa database: natural variants in human G protein‐coupled receptors , 2008, Human mutation.

[27]  G. Reiser,et al.  Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. , 2008, The Biochemical journal.

[28]  F. Ciruela,et al.  Light resonance energy transfer-based methods in the study of G protein-coupled receptor oligomerization. , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  R. Maggio,et al.  G protein‐coupled receptor oligomerization provides the framework for signal discrimination 1 , 2007, Journal of neurochemistry.

[30]  G. Milligan,et al.  Allosteric modulation of heterodimeric G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[31]  K. Fuxe,et al.  Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease , 2007 .

[32]  L. Miller,et al.  Transmembrane Segment IV Contributes a Functionally Important Interface for Oligomerization of the Class II G Protein-coupled Secretin Receptor* , 2007, Journal of Biological Chemistry.

[33]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[34]  T. Kent,et al.  G-protein-coupled receptor heterodimerization: assay technologies to clinical significance. , 2007, Current opinion in drug discovery & development.

[35]  Graeme Milligan,et al.  Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric beta2-adrenoceptor. , 2007, Cellular signalling.

[36]  M. Parmentier,et al.  Allosteric properties of G protein-coupled receptor oligomers. , 2007, Pharmacology & therapeutics.

[37]  P. Conn,et al.  G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo , 2007, Pharmacological Reviews.

[38]  A. Salahpour,et al.  Experimental challenge to a 'rigorous' BRET analysis of GPCR oligomerization , 2007, Nature Methods.

[39]  Thomas Huber,et al.  G protein-coupled receptors self-assemble in dynamics simulations of model bilayers. , 2007, Journal of the American Chemical Society.

[40]  R. Eglen,et al.  Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. , 2007, Assay and drug development technologies.

[41]  Joseph Shiloach,et al.  Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction , 2007, Proceedings of the National Academy of Sciences.

[42]  K. Ressler,et al.  Specificity of Olfactory Receptor Interactions with Other G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.

[43]  V. Setola,et al.  Modified Receptor Internalization upon Coexpression of 5-HT1B Receptor and 5-HT2B Receptors , 2007, Molecular Pharmacology.

[44]  Richard N. Zare,et al.  A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.

[45]  S. Rees,et al.  Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3 , 2007, Molecular Pharmacology.

[46]  K. Minneman,et al.  Heterodimerization and surface localization of G protein coupled receptors. , 2007, Biochemical pharmacology.

[47]  Graeme Milligan,et al.  The α1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function , 2007, Molecular Pharmacology.

[48]  P. Insel,et al.  Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. , 2007, Biochimica et biophysica acta.

[49]  Graeme Milligan,et al.  G protein-coupled receptor dimerisation: molecular basis and relevance to function. , 2007, Biochimica et biophysica acta.

[50]  S. Mazères,et al.  Physical Association between Neuropeptide FF and μ-Opioid Receptors as a Possible Molecular Basis for Anti-opioid Activity* , 2007, Journal of Biological Chemistry.

[51]  Michel Bouvier,et al.  International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers , 2007, Pharmacological Reviews.

[52]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[53]  B. O'dowd,et al.  D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum , 2007, Proceedings of the National Academy of Sciences.

[54]  K. Fuxe,et al.  Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. , 2007, Movement disorders : official journal of the Movement Disorder Society.

[55]  Graeme Milligan,et al.  The specificity and molecular basis of α1-adrenoceptor and CXCR chemokine receptor dimerization , 2007, Journal of Molecular Neuroscience.

[56]  H. Lother,et al.  Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension , 2007, Journal of Molecular Neuroscience.

[57]  G. Milligan,et al.  BRET analysis of GPCR oligomerization: newer does not mean better , 2007, Nature Methods.

[58]  G. Milligan,et al.  Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function* , 2006, Journal of Biological Chemistry.

[59]  K. Jacobson,et al.  Computational prediction of homodimerization of the A3 adenosine receptor. , 2006, Journal of molecular graphics & modelling.

[60]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[61]  C. Combs,et al.  Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions , 2006, Molecular Cancer Therapeutics.

[62]  J. Mazurkiewicz,et al.  Serotonin 5-HT2C Receptor Homodimer Biogenesis in the Endoplasmic Reticulum , 2006, Journal of Biological Chemistry.

[63]  Graeme Milligan,et al.  G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. , 2006, Drug discovery today.

[64]  Krzysztof Palczewski,et al.  Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. , 2006, Current opinion in structural biology.

[65]  K. L. Martinez,et al.  FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Marta Filizola,et al.  Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Insel,et al.  Genetic variation in G-protein-coupled receptors – consequences for G-protein-coupled receptors as drug targets , 2005, Expert opinion on therapeutic targets.

[68]  David J. Daniels,et al.  Interaction of Bivalent Ligand KDN21 with Heterodimeric δ-κ Opioid Receptors in Human Embryonic Kidney 293 Cells , 2005, Molecular Pharmacology.

[69]  B. O'dowd,et al.  D1 and D2 Dopamine Receptors Form Heterooligomers and Cointernalize after Selective Activation of Either Receptor , 2005, Molecular Pharmacology.

[70]  Graeme Milligan,et al.  The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities* , 2005, Journal of Biological Chemistry.

[71]  K. Palczewski,et al.  Diversifying the repertoire of G protein-coupled receptors through oligomerization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Jamie Fong,et al.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[73]  M. le Maire,et al.  Monomeric G-protein-coupled receptor as a functional unit. , 2005, Biochemistry.

[74]  Michel Bouvier,et al.  Methods to monitor the quaternary structure of G protein‐coupled receptors , 2005, The FEBS journal.

[75]  C. Hague,et al.  Heterodimerization with β2-Adrenergic Receptors Promotes Surface Expression and Functional Activity of α1D-Adrenergic Receptors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[76]  A. Finazzi-Agro’,et al.  The importance of being dimeric , 2004, The FEBS journal.

[77]  C. Hague,et al.  Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. , 2005, The Journal of pharmacology and experimental therapeutics.

[78]  David J. Daniels,et al.  Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. , 2005, Molecular pharmacology.

[79]  Krzysztof Palczewski,et al.  Oligomerization of G protein-coupled receptors: past, present, and future. , 2004, Biochemistry.

[80]  J. Banères,et al.  Cooperative Conformational Changes in a G-protein-coupled Receptor Dimer, the Leukotriene B4 Receptor BLT1* , 2004, Journal of Biological Chemistry.

[81]  J. Matthews,et al.  The power of two: protein dimerization in biology. , 2004, Trends in biochemical sciences.

[82]  G. Milligan,et al.  Multiple Interactions between Transmembrane Helices Generate the Oligomeric α1b-Adrenoceptor , 2004, Molecular Pharmacology.

[83]  Graeme Milligan,et al.  Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[84]  K. Fuxe,et al.  Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. , 2004, Analytical chemistry.

[85]  K. Ressler,et al.  Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Jean-François Mercier,et al.  Homodimerization of the β2-Adrenergic Receptor as a Prerequisite for Cell Surface Targeting* , 2004, Journal of Biological Chemistry.

[87]  J. W. Wells,et al.  Oligomeric potential of the M2 muscarinic cholinergic receptor , 2004, Journal of neurochemistry.

[88]  Graeme Milligan,et al.  G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology , 2004, Molecular Pharmacology.

[89]  C. Hague,et al.  Cell Surface Expression of α1D-Adrenergic Receptors Is Controlled by Heterodimerization with α1B-Adrenergic Receptors* , 2004, Journal of Biological Chemistry.

[90]  C. Hague,et al.  Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors. , 2004, The Journal of biological chemistry.

[91]  N. Ryba,et al.  The Receptors for Mammalian Sweet and Umami Taste , 2003, Cell.

[92]  H. Rockman,et al.  Dual Inhibition of &bgr;-Adrenergic and Angiotensin II Receptors by a Single Antagonist: A Functional Role for Receptor–Receptor Interaction In Vivo , 2003, Circulation.

[93]  J. Klco,et al.  C5a Receptor Oligomerization , 2003, Journal of Biological Chemistry.

[94]  B. O'dowd,et al.  D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. , 2003, Biochemistry.

[95]  Pierre Casellas,et al.  Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor , 2003, Journal of Biological Chemistry.

[96]  Joseph Parello,et al.  Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. , 2003, Journal of molecular biology.

[97]  R. Lefkowitz,et al.  Regulation of G protein-coupled receptor signaling by scaffold proteins. , 2002, Circulation research.

[98]  B. O'dowd,et al.  Oligomerization of opioid receptors: generation of novel signaling units. , 2002, Current opinion in pharmacology.

[99]  G. Milligan,et al.  Protein-protein interactions at G-protein-coupled receptors. , 2001, Trends in pharmacological sciences.

[100]  H. Lother,et al.  Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness , 2001, Nature Medicine.

[101]  S. Rees,et al.  Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and Bioluminescence Resonance Energy Transfer , 2001, The Journal of Biological Chemistry.

[102]  L. Devi,et al.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Y. Jan,et al.  A Trafficking Checkpoint Controls GABAB Receptor Heterodimerization , 2000, Neuron.

[104]  Michel Bouvier,et al.  Functional Significance of Oligomerization of G-protein-coupled Receptors , 2000, Trends in Endocrinology & Metabolism.

[105]  S. Rees,et al.  Chimaeric Gα proteins: their potential use in drug discovery , 1999 .

[106]  S. Rees,et al.  Chimaeric G alpha proteins: their potential use in drug discovery. , 1999, Trends in pharmacological sciences.

[107]  Alan Wise,et al.  Heterodimerization is required for the formation of a functional GABAB receptor , 1998, Nature.

[108]  B. Borowsky,et al.  GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. , 1998, Nature.

[109]  L. Devi,et al.  Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.

[110]  P. Seeman,et al.  Dopamine D2 receptor dimers and receptor-blocking peptides. , 1996, Biochemical and biophysical research communications.

[111]  Michel Bouvier,et al.  A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.

[112]  Pierre Corvol,et al.  Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling , 1996, The Journal of Biological Chemistry.

[113]  G. Barsh,et al.  Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha 2-C10 homolog responsible for an interspecies variation in antagonist binding. , 1992, Molecular pharmacology.